The new face of age-related macular degeneration [6]

Canadian Journal of Ophthalmology

Volumn 42, Issue 4, 2007, Pages 629-630

  Giuliari, Gian Paolo ^a   Ciardella, Antonio P ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN;

ANGIOGENESIS; HUMAN; LETTER; PHYSICIAN; RECURRENT DISEASE; RETINA MACULA AGE RELATED DEGENERATION; VASCULARIZATION; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 34748839031     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.3129/I07-086     Document Type: Letter

References (4)

1. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1991;109:1220-31.
2. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002;22:143-52.
3. Gonzales CR. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina 2005;25:815-27.
4. Schmidt-Erfurth U. Two-year efficacy and safety results from the MARINA study. Paper presented at 24th Annual American Society of Retina Specialists and 6th Annual European VitreoRetinal Society Meeting; September 9-13, 2006; Cannes, France.